Top

Published in:

01-12-2017 | Short Commentary

Disease reactivation after switching from natalizumab to daclizumab

Authors: Timo Uphaus, Christoph Oberwittler, Sergiu Groppa, Frauke Zipp, Stefan Bittner

Published in: Journal of Neurology | Issue 12/2017

Abstract

Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment.

Schwab N, Schneider-Hohendorf T, Pignolet B et al (2016) Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 3:e195CrossRefPubMedPubMedCentral

Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F (2014) Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 261:1170–1177CrossRefPubMed

Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G (2015) Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord 8:233–238CrossRefPubMedPubMedCentral

Berger B, Baumgartner A, Rauer S et al (2015) Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol 282:118–122CrossRefPubMed

Alping P, Frisell T, Novakova L et al (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79:950–958CrossRefPubMed

Rasenack M, Derfuss T (2016) Disease activity return after natalizumab cessation in multiple sclerosis. Expert Rev Neurother 16:587–594CrossRefPubMed

Cohen M, Maillart E, Tourbah A et al (2014) Club Francophone de la Sclerose en Plaques, Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 71:436–441CrossRefPubMed

Fox RJ, Cree BA, De Seze J et al (2014) Restore, MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 82:1491–1498CrossRefPubMedPubMedCentral

Iaffaldano P, Lucisano G, Pozzilli C et al (2015) Italian iMed-Web, Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain: J Neurol 138:3275–3286CrossRef

10.

Kappos L, Radue EW, Comi G, T.s. group et al (2015) Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology 85:29–39CrossRefPubMedPubMedCentral

11.

Jokubaitis VG, Li V, Kalincik T, M.S.S. Group et al (2014) Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82:1204–1211CrossRefPubMedPubMedCentral

12.

Bielekova B, Richert N, Howard T et al (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101:8705–8708CrossRefPubMedPubMedCentral

Title: Disease reactivation after switching from natalizumab to daclizumab
Authors: Timo Uphaus
Christoph Oberwittler
Sergiu Groppa
Frauke Zipp
Stefan Bittner
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 12/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8622-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Disease reactivation after switching from natalizumab to daclizumab

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2017

Reversible amygdala enlargement: a longitudinal observation of a patient with elderly onset temporal lobe epilepsy

An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease

Prevalence and clinical characteristics of cortical superficial siderosis in patients with acute stroke

Cannabidiol as a treatment for epilepsy

A novel mutation of VAPB in one Chinese familial amyotrophic lateral sclerosis pedigree and its clinical characteristics

Can developmental venous anomalies cause seizures?